Department of Surgery, Division of Hepato-Biliary and Pancreatic Surgery, Asan Medical Center, University of Ulsan college of Medicine, Seoul, South Korea.
Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
J Hepatobiliary Pancreat Sci. 2021 Nov;28(11):967-982. doi: 10.1002/jhbp.853. Epub 2020 Nov 10.
Owing to concerns regarding adequate oncological outcomes and perioperative complications, minimally invasive distal pancreatectomy (MIDP) for pancreatic ductal adenocarcinoma (PDAC) has limited generalizability. The aim of this study was to assess the perioperative and oncologic outcomes of MIDP compared with open distal pancreatectomy (ODP) for resectable PDAC after propensity score matching (PSM).
The patients who underwent MIDP and ODP for PDAC between January 2010 and December 2017 were retrospectively reviewed. Demographics, perioperative outcomes, pathological outcomes, and overall and disease-free survival data were collected to compare MIDP and ODP. After PSM, perioperative and oncologic outcomes were analyzed.
A total of 156 MIDP patients were compared with 156 ODP patients for resectable PDAC after PSM. Tumor size, TNM stage, differentiation, harvested lymph nodes, and positive lymph nodes were not different except for R1 resection and lymphovascular invasion between the MIDP and ODP groups. Operation times, overall complications, POPF, and adjuvant treatment were also not different between the two groups. The MIDP group had shorter hospital stays (10.0 vs 13.4 days, P < 0.001) and shorter interval times from surgery to adjuvant treatment (37.6 days vs 46.0 days, P = 0.002) than the ODP group. The MIDP group had better overall survival (34.9 vs 24.5 months, P = 0.012) and disease-free survival (16.2 vs 10.3 months, P = 0.001).
Minimally invasive distal pancreatectomy has advantages with respect to postoperative hospital stay, interval between surgery, and adjuvant treatment. MIDP is associated with the possibility of improved survival rate for resectable PDAC.
由于对肿瘤学结果和围手术期并发症的担忧,微创远端胰腺切除术(MIDP)治疗胰腺导管腺癌(PDAC)的应用具有一定局限性。本研究旨在通过倾向评分匹配(PSM)评估 MIDP 与开腹远端胰腺切除术(ODP)治疗可切除 PDAC 的围手术期和肿瘤学结果。
回顾性分析 2010 年 1 月至 2017 年 12 月期间接受 MIDP 和 ODP 治疗 PDAC 的患者。收集人口统计学、围手术期结果、病理结果以及总生存和无病生存数据,以比较 MIDP 和 ODP。PSM 后分析围手术期和肿瘤学结果。
共 156 例 MIDP 患者与 156 例 ODP 患者进行了 PSM 后可切除 PDAC 的比较。MIDP 和 ODP 两组除 R1 切除和血管淋巴管侵犯外,肿瘤大小、TNM 分期、分化程度、采集的淋巴结和阳性淋巴结无差异。两组手术时间、总体并发症、POPF 和辅助治疗无差异。MIDP 组的住院时间(10.0 天 vs. 13.4 天,P<0.001)和手术至辅助治疗的间隔时间(37.6 天 vs. 46.0 天,P=0.002)均短于 ODP 组。MIDP 组的总生存率(34.9 个月 vs. 24.5 个月,P=0.012)和无病生存率(16.2 个月 vs. 10.3 个月,P=0.001)均优于 ODP 组。
微创远端胰腺切除术具有术后住院时间、手术间隔和辅助治疗时间短的优势。MIDP 与可切除 PDAC 患者生存率提高的可能性相关。